| Title |
Lutetium-labelled peptides for therapy of neuroendocrine tumours
|
|---|---|
| Published in |
European Journal of Nuclear Medicine and Molecular Imaging, March 2012
|
| DOI | 10.1007/s00259-011-2039-y |
| Pubmed ID | |
| Authors |
B. L. R. Kam, J. J. M. Teunissen, E. P. Krenning, W. W. de Herder, S. Khan, E. I. van Vliet, D. J. Kwekkeboom |
| Abstract |
Treatment with radiolabelled somatostatin analogues is a promising new tool in the management of patients with inoperable or metastasized neuroendocrine tumours. Symptomatic improvement may occur with (177)Lu-labelled somatostatin analogues that have been used for peptide receptor radionuclide therapy (PRRT). The results obtained with (177)Lu-[DOTA(0),Tyr(3)]octreotate (DOTATATE) are very encouraging in terms of tumour regression. Dosimetry studies with (177)Lu-DOTATATE as well as the limited side effects with additional cycles of (177)Lu-DOTATATE suggest that more cycles of (177)Lu-DOTATATE can be safely given. Also, if kidney-protective agents are used, the side effects of this therapy are few and mild and less than those from the use of (90)Y-[DOTA(0),Tyr(3)]octreotide (DOTATOC). Besides objective tumour responses, the median progression-free survival is more than 40 months. The patients' self-assessed quality of life increases significantly after treatment with (177)Lu-DOTATATE. Lastly, compared to historical controls, there is a benefit in overall survival of several years from the time of diagnosis in patients treated with (177)Lu-DOTATATE. These findings compare favourably with the limited number of alternative therapeutic approaches. If more widespread use of PRRT can be guaranteed, such therapy may well become the therapy of first choice in patients with metastasized or inoperable neuroendocrine tumours. |
X Demographics
The data shown below were collected from the profiles of 5 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 20% |
| Canada | 1 | 20% |
| Australia | 1 | 20% |
| Unknown | 2 | 40% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 3 | 60% |
| Practitioners (doctors, other healthcare professionals) | 1 | 20% |
| Scientists | 1 | 20% |
Mendeley readers
The data shown below were compiled from readership statistics for 246 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Germany | 1 | <1% |
| Korea, Republic of | 1 | <1% |
| Brazil | 1 | <1% |
| Canada | 1 | <1% |
| Mexico | 1 | <1% |
| United States | 1 | <1% |
| Unknown | 240 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 43 | 17% |
| Student > Ph. D. Student | 32 | 13% |
| Student > Master | 32 | 13% |
| Other | 28 | 11% |
| Student > Bachelor | 23 | 9% |
| Other | 53 | 22% |
| Unknown | 35 | 14% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 92 | 37% |
| Physics and Astronomy | 27 | 11% |
| Chemistry | 22 | 9% |
| Pharmacology, Toxicology and Pharmaceutical Science | 16 | 7% |
| Agricultural and Biological Sciences | 15 | 6% |
| Other | 35 | 14% |
| Unknown | 39 | 16% |
Attention Score in Context
This research output has an Altmetric Attention Score of 13. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 07 April 2022.
All research outputs
#2,463,785
of 23,806,312 outputs
Outputs from European Journal of Nuclear Medicine and Molecular Imaging
#180
of 3,083 outputs
Outputs of similar age
#14,709
of 158,166 outputs
Outputs of similar age from European Journal of Nuclear Medicine and Molecular Imaging
#2
of 26 outputs
Altmetric has tracked 23,806,312 research outputs across all sources so far. Compared to these this one has done well and is in the 89th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,083 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.1. This one has done particularly well, scoring higher than 99% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 158,166 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 90% of its contemporaries.
We're also able to compare this research output to 26 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 92% of its contemporaries.